Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 210

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 210
---
2025, Wainwright has incurred $0 in out -of-pocketexpenses. Dr. Kira Sheinerman, the co -founderof DiamiR, is currently a managing director of Wainwright and shall be appointed to the Combined Company’s board of directors. On July 14, 2025, following the review, approval, and consent obtained from each of the Aptorum and DiamiR Board of Directors, Aptorum, DiamiR, and the newly formed Merger Sub executed the Merger Agreement, in addition to the entry into the Voting Agreement with Ian Huen (as described in this proxy and prospectus), the Managed Services Agreement, and the Intellectual Property Agreement. Aptorum’s Reasons for the Merger Since inception, the Company has sought to maximize shareholder value by licensing and acquiring technologies that have scientific merit and ultimately, meaningful market value after commercialization. We believe great opportunity exists for therapeutic agents developed for CNS indications, including neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as certain cancers like glioblastoma and neuroblastoma. Due to the heterogeneity of these diseases, there is a wide spectrum of clinical manifestations and outcomes in patients with these conditions. Therefore, there is a strong need for accurate, minimally invasive biomarkers reflective of pathophysiological processes underlying these diseases that can be used for disease progression and treatment response monitoring. As such, the Company’s management finds great value in DiamiR’s innovation and proprietary technology. DiamiR’s platform technology, which is based on targeted selection and quantitative analysis of organ -enriched, including brain -enriched, microRNA (miRNAs) detectable in blood plasma, has a potential to provide molecular diagnostic solutions for risk assessment and monitoring of neuro and other indications in clinical trials, which we believe will enable more effective drug development for these indications. DiamiR’s CLIA/CAP -certifiedlab offers and is planning to offer additional genetic and protein biomarkers used in clinical trials for. For example, DiamiR’s APOE genotyping test (APOE e4 allele is an established risk factor of AD, while APOE e2 is considered to be neuroprotective), which has been approved by NY State and CAP, can be used as a screening tool for enrollment into clinical trials targeting APOE e4 carriers or non -carriers. The Company is aware of a need in such test first -handas it holds a position in a private life sciences company